What is AMPIO PHARMS INC's earnings per share (EPS)?

AMPIO PHARMS INC (AMPE) reported diluted earnings per share of -$10.66 for fiscal year 2023. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AMPIO PHARMS INC (AMPE) Financials

AMPE

FY2023 annual

Revenue Not reported for FY2023

Net Income -$8.6M +47.2% YoY

EPS (Diluted) -$10.66 YoY not available

Operating Cash Flow -$8.6M +59.5% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2023, ended Dec 31, 2023 Reported Mar 27, 2024 Currency USD FYE December

Newest figures come from the 10-K for FY2023, filed Mar 27, 2024. Each column of the statement tables below links to the filing it was taken from.

This page shows AMPIO PHARMS INC (AMPE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AMPE FY2023 2026-08-30

Ampio’s development-stage model remains a cash consumer, with 2023 loss improvement driven mainly by sharply lower spending.

In FY2023, the company recorded a net loss of -$8.6M and burned $8.6M in operating cash, so accounting and cash results largely agree rather than showing a large noncash earnings gap. The improvement from FY2022 therefore looks expense-led: R&D fell to $2.4M while SG&A fell to $7.1M, not like scale-driven operating leverage.

Earlier negative operating cash flow was paired with positive financing cash flow, but FY2023 financing was zero; liabilities of $2.4M were supported by equity of $3.4M, indicating a smaller, less externally funded balance sheet than in earlier periods. Liquidity also tightened: the current ratio moved from 11.2x in FY2022 to 2.4x in FY2023.

Reported revenue is absent across the periods, while FY2023 operating costs still exceeded $9.5M; this combination describes a business funding development and corporate overhead without a reported sales base. The reported liquidity comparison was 5.7 months of annual operating outflow, framing the cash position against the latest spending rate rather than against revenue.

Financial Health Signals

Financial health score not available

AMPIO PHARMS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

AMPIO PHARMS INC passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

AMPIO PHARMS INC reported a net loss of $8.6M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

-$2.48

QoQ-62.1%

AMPIO PHARMS INC earned -$2.48 per diluted share (EPS) in Q4 2023. Against the prior quarter it is down 62.1%.

Revenue

Not reported for Q4 2023.

EBITDA

Not reported for Q4 2023.

Net Income

Not reported for Q4 2023.

Cash & Balance Sheet

Cash & Debt

$4.1M

YoY-67.7%

QoQ-36.1%

5Y CAGR-11.6%

AMPIO PHARMS INC held $4.1M in cash as of Q4 2023; long-term debt is not reported for that period.

Shares Outstanding

QoQ+36.5%

5Y CAGR-60.0%

10Y CAGR-30.3%

AMPIO PHARMS INC had 1M shares outstanding in Q4 2023. Against the prior quarter it is up 36.5%.

Free Cash Flow

Not reported for Q4 2023.

Dividends Per Share

Not reported for Q4 2023.

Margins & Returns

None of these metrics is reported for Q4 2023.

Capital Allocation

None of these metrics is reported for Q4 2023.

AMPE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMPE quarterly income statement

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.2M+1413.9%	$77K+53.6%	$50K	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$369K	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$793K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.4M-72.6%	$8.9M-25.1%	$11.9M+29.7%	$9.2M-27.3%	$12.6M+84.8%	$6.8M	N/A	$10.5M-30.2%	$15.1M-32.8%	$22.5M+35.5%	$16.6M+174.6%	$6.0M-9.1%	$6.6M+237.1%	$2.0M	N/A
SG&A Expenses	$7.1M-38.3%	$11.5M+32.2%	$8.7M+30.2%	$6.7M+11.9%	$6.0M+36.7%	$4.4M-17.1%	$5.3M-19.6%	$6.5M-56.8%	$15.1M+23.8%	$12.2M+63.5%	$7.5M+28.3%	$5.8M+29.3%	$4.5M	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$33.3M+14.8%	-$39.1M-62.6%	-$24.0M	N/A	N/A	N/A	N/A
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$32.5M+16.1%	-$38.7M-62.1%	-$23.9M	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	$5K	N/A	N/A	-$334K-1599.2%	$22K+81.2%	$12K	N/A	$8K-57.2%	$20K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A
Net Income	-$8.6M+47.2%	-$16.3M+4.3%	-$17.1M-7.4%	-$15.9M-16.6%	-$13.6M-140.1%	$34.0M+165.5%	-$51.9M-170.8%	-$19.2M+40.1%	-$32.0M+16.0%	-$38.1M-58.8%	-$24.0M-107.1%	-$11.6M+36.9%	-$18.4M	N/A	-$1.5M
EPS (Basic)	-$10.66+50.8%	-$21.68-1580.6%	-$1.29-1333.3%	-$0.09+10.0%	-$0.10-121.7%	$0.46	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$10.66	-$29.32	-$1.51	-$0.09	-$0.14-16.7%	-$0.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	810,113	753,615	14M	173M	131M+44.0%	91M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
R&D Expenses	N/A	$329K-88.0%	$344K-80.3%	$524K-85.8%	N/A	$2.7M+5.9%	$1.7M-23.3%	$3.7M+60.6%
SG&A Expenses	N/A	$1.1M-64.0%	$1.2M-62.5%	$3.8M+16.3%	N/A	$3.0M+136.7%	$3.2M+131.8%	$3.3M+115.6%
Net Income	N/A	-$1.2M+80.8%	-$1.4M+33.8%	-$4.0M+29.4%	N/A	-$6.4M-76.7%	-$2.1M+41.8%	-$5.6M-53.7%
EPS (Basic)	-$2.48-1671.4%	-$1.53+82.0%	-$0.09+35.7%	-$0.26+29.7%	-$0.14+70.2%	-$8.51-3051.9%	-$0.14-600.0%	-$0.37-1750.0%
EPS (Diluted)	-$2.48	-$1.53	-$0.09	-$0.26	-$0.18	-$10.06	-$0.33	-$0.46
Diluted Shares (Avg)	N/A	804,158	15M	15M	N/A	753,620	15M	15M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Interest Expense, Income Tax.

AMPE Balance Sheet

AMPE quarterly balance sheet

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Total Assets	$5.7M-57.8%	$13.6M-65.0%	$38.8M+69.7%	$22.9M+63.4%	$14.0M-0.2%	$14.0M-8.4%	$15.3M+12.6%	$13.6M-73.0%	$50.4M-28.2%	$70.3M+95.1%	$36.0M+39.4%	$25.8M+32.7%	$19.5M+2541.6%	$738K	N/A
Current Assets	$5.7M-57.0%	$13.3M-62.6%	$35.6M+92.7%	$18.5M+124.2%	$8.3M+2.7%	$8.0M-4.9%	$8.4M+56.3%	$5.4M-81.5%	$29.2M-43.0%	$51.3M+93.9%	$26.4M+48.2%	$17.8M+56.5%	$11.4M+1446.5%	$738K	N/A
Cash & Equivalents	$4.1M-67.7%	$12.7M-62.7%	$33.9M+95.4%	$17.3M+165.6%	$6.5M-13.9%	$7.6M-7.6%	$8.2M+67.7%	$4.9M-81.8%	$27.0M-46.4%	$50.3M+91.3%	$26.3M+48.8%	$17.7M+55.6%	$11.4M+1592.6%	$671K+832.6%	$72K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$221K	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M+32.1%	$1.8M-84.4%	$11.5M+115.1%	$5.4M-29.0%	$7.6M-14.1%	$8.8M-82.2%	$49.5M+610.9%	$7.0M-44.3%	$12.5M+159.7%	$4.8M+71.5%	$2.8M+39.0%	$2.0M+17.1%	$1.7M-63.7%	$4.7M	N/A
Current Liabilities	$2.4M+99.3%	$1.2M-76.7%	$5.1M+179.3%	$1.8M-57.2%	$4.3M+209.5%	$1.4M-64.3%	$3.9M+81.7%	$2.1M-61.3%	$5.5M+49.9%	$3.7M+48.8%	$2.5M+51.1%	$1.6M+26.7%	$1.3M-72.8%	$4.7M	N/A
Non-Current Liabilities	$0-100.0%	$607K-90.5%	$6.4M+81.7%	$3.5M+7.9%	$3.3M-55.8%	$7.4M-83.8%	$45.6M+845.0%	$4.8M-30.8%	$7.0M+517.4%	$1.1M+241.1%	$331K-13.1%	$381K-11.6%	$431K	$0	N/A
Total Equity	$3.4M-71.5%	$11.8M-56.8%	$27.3M+55.8%	$17.5M+171.9%	$6.4M+23.1%	$5.2M+115.3%	-$34.2M-615.2%	$6.6M-82.1%	$37.0M-44.0%	$66.1M+99.9%	$33.1M+38.8%	$23.8M+34.2%	$17.8M+543.1%	-$4.0M-1395.9%	-$268K
Retained Earnings	-$242.5M-3.7%	-$233.9M-7.5%	-$217.6M-8.5%	-$200.5M-8.6%	-$184.6M-8.0%	-$171.0M+16.6%	-$205.0M-33.9%	-$153.1M-14.3%	-$133.9M-31.4%	-$101.9M-59.8%	-$63.8M	N/A	N/A	N/A	N/A

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
Total Assets	$5.7M-57.8%	$7.6M-59.4%	$9.1M-66.4%	$10.7M-67.3%	$13.6M-65.0%	$18.8M-16.2%	$27.2M+1.9%	$32.8M+50.9%
Current Assets	$5.7M-57.0%	$7.6M-58.3%	$9.1M-62.9%	$10.7M-64.1%	$13.3M-62.6%	$18.3M-3.4%	$24.6M+7.6%	$29.9M+69.9%
Cash & Equivalents	$4.1M-67.7%	$6.4M-62.2%	$7.0M-69.6%	$10.4M-64.1%	$12.7M-62.7%	$16.9M-1.0%	$22.9M+11.4%	$28.8M+82.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.4M+32.1%	$2.3M-54.5%	$2.6M-63.6%	$2.9M-72.9%	$1.8M-84.4%	$5.0M-4.0%	$7.1M+12.1%	$10.5M+112.8%
Current Liabilities	$2.4M+99.3%	$2.3M-42.1%	$2.5M-50.9%	$2.7M-51.6%	$1.2M-76.7%	$3.9M+64.4%	$5.1M+57.1%	$5.5M+236.5%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$94K-95.4%	$185K-96.3%	$607K-90.5%	$1.1M-62.1%	$2.0M-34.6%	$5.0M+51.4%
Total Equity	$3.4M-71.5%	$5.4M-61.2%	$6.6M-67.4%	$7.9M-64.6%	$11.8M-56.8%	$13.8M-19.7%	$20.1M-1.2%	$22.3M+32.8%
Retained Earnings	-$242.5M-3.7%	-$240.5M-3.8%	-$239.2M-6.2%	-$237.9M-6.6%	-$233.9M-7.5%	-$231.7M-9.6%	-$225.3M-8.5%	-$223.2M-9.3%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

AMPE Cash Flow Statement

AMPE quarterly cash flow statement

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Operating Cash Flow	-$8.6M+59.5%	-$21.1M-50.0%	-$14.1M+4.3%	-$14.7M+4.3%	-$15.4M-26.7%	-$12.1M-6.4%	-$11.4M+22.0%	-$14.6M+44.7%	-$26.4M+14.0%	-$30.7M-60.7%	-$19.1M-96.9%	-$9.7M-6.4%	-$9.1M-247.4%	-$2.6M	N/A
Depreciation & Amortization	$122K-88.4%	$1.0M-4.2%	$1.1M-7.1%	$1.2M-7.5%	$1.3M-0.7%	$1.3M+5.5%	$1.2M0.0%	$1.2M+47.2%	$825K+142.0%	$341K+147.5%	$138K+120.7%	$62K+46.6%	$43K	N/A	N/A
Stock-Based Compensation	$159K-89.1%	$1.5M-46.3%	$2.7M+113.3%	$1.3M+215.3%	$405K-8.8%	$444K-40.4%	$745K-50.9%	$1.5M-69.4%	$5.0M-30.9%	$7.2M+108.1%	$3.4M+126.5%	$1.5M-23.3%	$2.0M+52.9%	$1.3M	N/A
Capital Expenditures	N/A	$0-100.0%	$97K+54.0%	$63K+186.4%	$22K-96.1%	$564K+679.8%	$72K+956.8%	$7K-93.8%	$110K-98.7%	$8.7M+561.0%	$1.3M	N/A	$85K	N/A	N/A
Free Cash Flow	N/A	-$21.1M-48.9%	-$14.2M+4.1%	-$14.8M+4.0%	-$15.4M-21.3%	-$12.7M-10.7%	-$11.5M+21.5%	-$14.6M+44.9%	-$26.6M+32.6%	-$39.4M-92.8%	-$20.4M	N/A	-$9.2M	N/A	N/A
Investing Cash Flow	$0	$0+100.0%	-$97K-54.0%	-$63K-186.4%	-$22K+96.1%	-$564K-679.8%	-$72K-956.8%	-$7K+100.0%	-$18.1M-27.5%	-$14.2M-751.5%	-$1.7M-11201.6%	$15K+112.5%	-$120K	N/A	N/A
Financing Cash Flow	$0+100.0%	-$111K-100.4%	$30.7M+20.0%	$25.6M+78.4%	$14.4M+18.8%	$12.1M-18.4%	$14.8M+319.3%	$3.5M-83.3%	$21.2M-69.3%	$68.9M+134.3%	$29.4M+83.7%	$16.0M-19.7%	$19.9M+517.9%	$3.2M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$13.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$47K	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
Operating Cash Flow	-$2.3M+46.2%	-$555K+90.7%	-$3.4M+42.8%	-$2.3M+53.5%	-$4.3M-15.9%	-$5.9M-52.0%	-$5.9M-155.5%	-$4.9M-19.2%
Depreciation & Amortization	$0-100.0%	$0-100.0%	$0-100.0%	$122K-53.4%	$183K-30.4%	$347K+31.9%	$256K-6.6%	$262K-10.9%
Stock-Based Compensation	N/A	$46K-71.8%	$53K+161.6%	$23K-96.8%	N/A	$163K+246.8%	-$86K-228.4%	$716K+331.3%
Capital Expenditures	N/A	N/A	N/A	N/A	$0	$0-100.0%	$0	$0-100.0%
Free Cash Flow	N/A	N/A	N/A	N/A	-$4.3M-15.9%	-$5.9M-51.4%	-$5.9M-155.5%	-$4.9M-16.9%
Investing Cash Flow	$0	$0	N/A	N/A	$0	$0+100.0%	$0	$0+100.0%
Financing Cash Flow	$0	$0	$0	$0+100.0%	$0-100.0%	$0-100.0%	$0-100.0%	-$111K-104.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

AMPE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMPE quarterly financial ratios

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	68.2%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-2864.8%	-50882.4%	-48047.8%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-2753.7%	-49650.9%	-48017.1%	N/A	N/A	N/A	N/A
Return on Equity	-256.9%-118.3pp	-138.6%-76.0pp	-62.6%+28.2pp	-90.7%+120.8pp	-211.5%-860.6pp	649.1%	N/A	-288.9%-202.3pp	-86.5%-28.9pp	-57.7%+14.9pp	-72.6%-23.9pp	-48.6%+54.7pp	-103.4%	N/A	N/A
Return on Assets	-150.5%-30.3pp	-120.2%-76.3pp	-44.0%+25.5pp	-69.5%+27.9pp	-97.4%-339.6pp	242.2%+581.1pp	-338.8%-197.9pp	-140.9%-77.5pp	-63.5%-9.2pp	-54.3%+12.4pp	-66.7%-21.8pp	-44.9%+49.4pp	-94.2%	N/A	N/A
Current Ratio	2.41-8.8x	11.18+4.2x	6.96-3.1x	10.08+8.2x	1.93-3.9x	5.80+3.6x	2.18-0.4x	2.53-2.8x	5.30-8.6x	13.93+3.2x	10.69-0.2x	10.91+2.1x	8.83+8.7x	0.16	N/A
Debt-to-Equity	0.71+0.6x	0.15-0.3x	0.42+0.1x	0.31-0.9x	1.17-0.5x	1.68	N/A	1.05+0.7x	0.34+0.3x	0.070.0x	0.080.0x	0.080.0x	0.10	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.020.0x	0.000.0x	0.00	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-2284.3%	-51322.4%	-40889.1%	N/A	N/A	N/A	N/A

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
Return on Equity	N/A	-22.9%+23.4pp	-20.9%-10.6pp	-50.5%-25.2pp	N/A	-46.3%-25.3pp	-10.3%+7.2pp	-25.3%-3.5pp
Return on Assets	N/A	-16.1%+18.0pp	-15.0%-7.4pp	-37.1%-19.9pp	N/A	-34.0%-17.9pp	-7.6%+5.7pp	-17.2%-0.3pp
Current Ratio	2.41-8.8x	3.37-1.3x	3.67-1.2x	4.02-1.4x	11.18+4.2x	4.67-3.3x	4.85-2.2x	5.41-5.3x
Debt-to-Equity	0.71+0.6x	0.42+0.1x	0.390.0x	0.36-0.1x	0.15-0.3x	0.36+0.1x	0.350.0x	0.47+0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
AMPIO PHARMS INC AMPE	FY2023	N/A	-$8.6M	N/A	$3K	—
BETTER THERAPEUTICS INC BTTX	FY2022	N/A	-$39.8M	N/A	$5K	—
NOVACCESS GLOBAL INC XSNX	FY2024	$0	N/A	N/A	$12K	—
RENOVACARE INC RCAR	FY2021	N/A	-$4.5M	N/A	$9K	—

Where AMPIO PHARMS INC Ranks

Frequently Asked Questions

Is AMPIO PHARMS INC profitable?

No, AMPIO PHARMS INC (AMPE) reported a net income of -$8.6M in fiscal year 2023.

What is AMPIO PHARMS INC's return on equity (ROE)?

AMPIO PHARMS INC (AMPE) has a return on equity of -256.9% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.

What is AMPIO PHARMS INC's operating cash flow?

AMPIO PHARMS INC (AMPE) recorded an outflow of $8.6M in operating cash flow during fiscal year 2023, representing cash used by core business activities.

What are AMPIO PHARMS INC's total assets?

AMPIO PHARMS INC (AMPE) had $5.7M in total assets as of fiscal year 2023, including both current and long-term assets.

How much does AMPIO PHARMS INC spend on research and development?

AMPIO PHARMS INC (AMPE) invested $2.4M in research and development during fiscal year 2023.

How many shares does AMPIO PHARMS INC have outstanding?

AMPIO PHARMS INC (AMPE) had 1M shares outstanding as of fiscal year 2023.

What is AMPIO PHARMS INC's current ratio?

AMPIO PHARMS INC (AMPE) had a current ratio of 2.41 as of fiscal year 2023, which is generally considered healthy.

What is AMPIO PHARMS INC's debt-to-equity ratio?

AMPIO PHARMS INC (AMPE) had a debt-to-equity ratio of 0.71 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AMPIO PHARMS INC's return on assets (ROA)?

AMPIO PHARMS INC (AMPE) had a return on assets of -150.5% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

How does AMPIO PHARMS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2023, AMPIO PHARMS INC (AMPE) held $4.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.6M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is AMPIO PHARMS INC's Piotroski F-Score?

AMPIO PHARMS INC (AMPE) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AMPIO PHARMS INC's earnings high quality?

AMPIO PHARMS INC (AMPE) reported a net loss of $8.6M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.